Drug development: neoadjuvant opportunities in breast cancer

Keyphrases

• Breast Cancer 100%
• Neoadjuvant 100%
• Drug Development 100%
• Pathological Complete Response 100%
• New Agents 50%
• Neoadjuvant Setting 50%
• Clinical Trials 33%
• Improved Outcomes 33%
• Chemotherapy 33%
• Preoperative Therapy 33%
• Residual Disease 33%
• Meta-analysis 16%
• High Risk 16%
• Radiation Therapy 16%
• Adjuvant Therapy 16%
• Patient Demographics 16%
• Breast Reconstruction 16%
• Recurrent Disease 16%
• U.S. Food 16%
• Treatment Regimen 16%
• Breast Cancer Biology 16%
• Serial Biopsy 16%
• New Therapies 16%
• Breast Cancer Subtypes 16%
• Endocrine Therapy 16%
• Neoadjuvant Therapy 16%
• Complete Response Rate 16%
• Predictive Biomarker 16%
• Trastuzumab 16%
• New Targeted Therapy 16%
• HER2+ Breast Cancer 16%
• Aggressive Breast Cancer 16%
• Neoadjuvant Endocrine Therapy 16%

Nursing and Health Professions

• Breast Cancer 100%
• Drug Development 100%
• Minimal Residual Disease 50%
• Hormonal Therapy 50%
• Patient Population 25%
• Biopsy Technique 25%
• Recurrent Disease 25%
• Food and Drug Administration 25%
• Meta Analysis 25%
• Radiotherapy 25%
• Adjuvant Therapy 25%
• Biological Marker 25%
• Partial Mastectomy 25%
• Trastuzumab 25%
• Neoadjuvant Therapy 25%
• Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer 25%

Medicine and Dentistry

• Breast Cancer 100%
• Clinical Trial 50%
• Minimal Residual Disease 50%
• Hormone Therapy 50%
• Meta-Analysis 25%
• Biopsy Technique 25%
• Radiation Therapy 25%
• Adjuvant Therapy 25%
• Patient Population 25%
• Quadrantectomy 25%
• Recurrent Disease 25%
• Targeted Therapy 25%
• Neoadjuvant Therapy 25%
• Cancer Pathobiology 25%
• Biological Marker 25%
• Trastuzumab 25%
• Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer 25%